TranS1, a Wilmington, N.C.-based company focused on producing solutions for minimally invasive spine surgery, recently received FDA 510(k) clearance for the AxiaLIF 1L+ product line, according to a company news release.
The system is the next generation of the original AxiaLIF 1L system, indicated for L5-S1 lumbar fusion. The system is designed to allow more precise distraction capability and improvement in pull-out strength. The system also provides a biomechanically stable implant at the base of the spine.
The company plans a full commercial release of the system in the second half of 2011.
Read the TranS1 news release on the spine surgery system.
Read other coverage on TranS1:
- TranS1 Names Ken Reali New CEO
- TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease
The system is the next generation of the original AxiaLIF 1L system, indicated for L5-S1 lumbar fusion. The system is designed to allow more precise distraction capability and improvement in pull-out strength. The system also provides a biomechanically stable implant at the base of the spine.
The company plans a full commercial release of the system in the second half of 2011.
Read the TranS1 news release on the spine surgery system.
Read other coverage on TranS1:
- TranS1 Names Ken Reali New CEO
- TranS1 Reports 4Q Revenue of $5.9M, 6% Decrease